Impact of exogenous gonadotropin stimulation on circulatory and follicular fluid cytokine profiles. by Baskind, NE et al.
Clinical Study
Impact of Exogenous Gonadotropin Stimulation on
Circulatory and Follicular Fluid Cytokine Profiles
N. Ellissa Baskind,1 Nicolas M. Orsi,2 and Vinay Sharma1
1 The Leeds Centre for Reproductive Medicine, Leeds Teaching Hospitals NHS Trust, Seacroft Hospital,
York Road, LS14 6UH Leeds, UK
2Women’s Health Research Group, Leeds Institute of Cancer & Pathology, St James’s University Hospital,
Wellcome Trust Brenner Building, Beckett Street, LS9 7TF Leeds, UK
Correspondence should be addressed to N. Ellissa Baskind; ellissa@doctors.org.uk
Received 23 September 2014; Accepted 11 November 2014; Published 30 November 2014
Academic Editor: Stefania A. Nottola
Copyright © 2014 N. Ellissa Baskind et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. The natural cycle is the prototype to which we aspire to emulate in assisted reproduction techniques. Increasing
evidence is emerging that controlled ovarian hyperstimulation (COH) with exogenous gonadotropins may be detrimental to
oogenesis, embryo quality, and endometrial receptivity. This research aimed at assessing the impact of COH on the intrafollicular
milieu by comparing follicular fluid (FF) cytokine profiles during stimulated in vitro fertilization (IVF) and modified natural
cycle (MNC) IVF. Methods. Ten women undergoing COH IVF and 10 matched women undergoing MNC IVF were recruited
for this pilot study. 40 FF cytokine concentrations from individual follicles and plasma were measured by fluid-phase multiplex
immunoassay. Demographic/cycle/cytokine data were compared and correlations between cytokines were computed. Results. No
significant differences were found between COH andMNC groups for patient and cycle demographics, including outcome. Overall
mean FF cytokine levels were higher in the MNC group for 29/40 cytokines, significantly so for leukaemia inhibitory factor
and stromal cell-derived factor-1𝛼. Furthermore, FF MNC cytokine correlations were significantly stronger than for COH data.
Conclusions. These findings suggest that COH perturbs intrafollicular cytokine networks, in terms of both cytokine levels and their
interrelationships. This may impact oocyte maturation/fertilization and embryo developmental competence.
1. Introduction
Controlled ovarian hyperstimulation (COH) with gonadot-
ropins has improved success rates of in vitro fertilization
(IVF) by increasing the number and opportunity for selection
of embryos before transfer [1–3] as well as permitting the cry-
opreservation of supernumerary embryos for further fertility
treatment [4, 5].The basis of COH is to support the growth of
multiple follicles to the preovulatory stage, a process achieved
by bypassing physiological regulatory mechanisms. Urinary-
derived or recombinant follicle stimulating hormone (FSH)
is administered to increase serum concentrations above
the threshold required for dominant follicle selection, thus
enabling the entire cohort of recruited follicles to develop
and attain preovulatory status [4]. Luteinising hormone
(LH) is often coadministered although, following pituitary
downregulation, this is not essential for follicular develop-
ment as remnant basal LH levels are sufficient to stimulate
the theca cells. Administration of a GnRH analogue (long
protocol) or an antagonist (short protocol) that desensitizes
the pituitary is primarily used to prevent premature LH surge
as a consequence of supraphysiological serum oestradiol (E
2
)
levels which, if it occurs, can lead to premature luteinisation
and/or ovulation.
With few exceptions [6], the last two decades have wit-
nessed a mounting body of evidence indicating that ovarian
stimulation has a detrimental effect on oogenesis, embryo
quality, and endometrial receptivity [7–13]. More specifically,
Sharma et al. [7] and Pellicer et al. [14] demonstrated
that retrieval of >10 oocytes per woman adversely affected
their quality based on oocyte/embryo morphology, fertiliza-
tion, and implantation rates. More recently van der Gaast
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et al. [15] found 13 oocytes to be the optimum number
retrieved in order to achieve a pregnancy using a long
protocol, above which there was a fall in pregnancy rates.
An extreme example of the negative impact of COH is the
excessively high number of poor quality oocytes seen in ovar-
ian hyperstimulation syndrome (OHSS), which is putatively
attributable to detrimental supraphysiological E
2
levels [16].
These observations in humans are supported by a number
of rodent studies that investigated the impact of exogenous
gonadotropin stimulation on oocytes and demonstrated a
delay in embryo development [17, 18]. It has been suggested
that gonadotropin stimulation may affect oocyte maturation
and the completion of meiosis, thus leading to an increased
risk of having aneuploid oocytes and/or embryos [10, 19]. As
such, in vitro maturation (IVM) has been proposed as an
alternative strategy since it reduces exposure to exogenous
gonadotropin stimulation, but the process itself introduces
a host of other variables/complications (e.g., disruption of
the meiotic spindle) that do not allow a fair comparison
of these approaches to be made [20]. von Wolff et al. [21]
recently demonstrated a varying endocrine follicular milieu
together with the concentration of putativemarkers of oocyte
quality, specifically anti-Mu¨llerian hormone (AMH) between
NC and COH FF, and suggest that this may be the cause
for the lower oocyte quality following COH compared with
naturally matured oocytes.
There has also been some concern that suppressed LH
concentrations in the late follicular phase may be detrimen-
tal through downstream perturbations in follicular steroid
synthesis. Consequently, stimulation protocols incorporating
exogenous LH were developed, resulting in an increase in
the percentage of diploid and good quality embryos obtained
[22, 23]. By contrast, other investigators have reported a
reduction in fertility and increased risk of miscarriage when
incorporating exogenous LH into protocols [24, 25]. Such
contradictory findings support the notion of a “LH window”
below which E
2
production is inadequate and above which
LH may begin premature luteinisation and be detrimental to
follicular development [26]. vonWolff et al. [21] postulate that
the reduced levels of intrafollicular AMH they demonstrated
following COH compared with NC may be attributed to
LH suppression, resulting initially in low follicular androgen
concentrations, and subsequently to low AMH production
which in turn may be responsible for lower oocyte qual-
ity.
Natural cycle IVF (NC-IVF) has been proposed as an
alternative treatment for older women and poor responders
[27]. Indeed, there has been a resurgence of interest in NC-
IVF for all patients in recent years because it avoids COH
and its potential sequelae. Moreover, this also supports the
international drive to reduce multiple pregnancies rates with
elective single embryo transfer and to minimise complica-
tions such as OHSS [28–30]. Pelinck et al. [1] conducted
a systematic review of 1,800 natural IVF cycles reported
between 1989 and 2000 and concluded that NC-IVF has a
pregnancy rate of less than 10% per cycle. More recent reports
concur, presenting a similar 15.2% live birth rate per initiated
cycle in all reported unstimulated NCs in women <35 years
(𝑛 = 795) in the United States (2006-2007) [31].
A compromise between these approaches has been
described: mild ovarian stimulation IVF. This method incor-
porates the use of low dose gonadotropin stimulation
together with a gonadotropin releasing hormone (GnRH)
antagonist aimed at generating fewer than eight oocytes per
cycle [32]. The term modified natural cycle IVF (MNC-IVF)
is applied when drugs (e.g., human chorionic gonadotropin
(hCG)) are used to induce final oocyte maturation whereby a
GnRH antagonist is administered during a spontaneous cycle
to reduce the risk of cancellation [33] and/or where luteal
support is provided.
During folliculogenesis, follicular fluid (FF) composition
exhibits dynamic changes as individual follicular cell types
respond to gonadotropins by secreting different hormones
and cytokines [34, 35]. As growth factors regulating all
stages of folliculogenesis, cytokines have been shown to
govern the development/function of somatic cells and the
oocyte as well as the composition of FF [36–42]. Given that
oocyte quality influences subsequent embryo viability [43],
it has been suggested that the disruption in the balance of
these intrafollicular mediators following COHmay influence
cycle outcome [44–52]. The correct regulation of cytokine
networks is essential to support normal physiology and
this central role is underscored by the fact that inflam-
matory/immune dysfunctions underpin many pathological
reproductive conditions, resulting in both local and systemic
changes in cytokine profiles [53–55].
Studies have measured individual FF cytokines through-
out the menstrual cycle. For example, the levels of interleu-
kin- (IL-) 8, a chemotactic and angiogenic cytokine essential
to folliculogenesis, have been found to rise from the midfol-
licular to the late follicular phase.These levels are comparable
to those found during a COH cycle [56], implying that
granulosa cell (GC) and theca cell (TC) IL-8 secretion is
a true physiological phenomenon associated with follicular
growth/maturation rather than resulting from gonadotropin
stimulation. In vitro enhancement of IL-8 secretion by cul-
tured GCs and TCs was evident following exposure to IL-1𝛼
and IL-1𝛽, but not tumour necrosis factor- (TNF-) 𝛼, suggest-
ing that IL-8 is both gonadotropin and cytokine-induced and
may thus be involved in the hormonally regulated stages of
folliculogenesis and ovulation [57].
Although cytokines are readily detected in FF, the com-
plexity of their network regulationmakes their study in isola-
tion difficult to interpret. In view of their biological properties
(pleiotropism, synergy, antagonism, functional redundancy,
and differential sensitivity) [58–60], cytokines should ide-
ally be investigated in terms of their interrelationships as
much as in terms of their absolute concentrations. Whilst
a recent study by Bersinger et al. [61] failed to demonstrate
a difference in 13 FF cytokines between women undergoing
NC and COH IVF, no specific attention was paid towards
the complex interrelations within the cytokine networks.
To date, there has been a paucity of studies focusing on
minimal stimulation regimens and MNCs, and comparisons
of isolated cytokine concentrations (e.g., vascular endothelial
growth factor (VEGF) in COH and NC-IVF) have been
inconsistent [62, 63]. Exogenous gonadotropins may disrupt
intrafollicular cytokine networks, in turn affecting oocyte
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developmental potential. Therefore, this pilot study aimed at
examining the impact of gonadotropins on the intrafollicular
cytokine milieu in MNC and following COH cycles.
2. Materials and Methods
2.1. Patient Recruitment and Sample Collection. From
November 2008 to March 2009, ten women who required
treatment with IVF/ICSI due to unexplained or male factor
infertility aged 25–35 years with a body mass index (BMI)
19–30 were selected to undergo MNC-IVF/intracytoplasmic
sperm injection (ICSI) at the Assisted Conception Unit, St
James’s University Hospital, Leeds, UK. These patients were
matched with ten women undergoing COH-IVF/ICSI. Only
nonsmokers and women who drank <6 units alcohol per
week were included. They were required to be ovulatory
(confirmed by transvaginal ultrasound scan (TVUSS), pro-
gesterone levels, or commercial LH surge kits within the
preceding three months) and have a normal endocrine
profile (early follicular phase FSH < 8.0 IU/L and E
2
50–
200 pmol/L), a negative infection screen (including negative
serumChlamydia antigens), and normal pelvic anatomy con-
firmed by TVUSS and laparoscopy. Furthermore, they were
required to have no risk factors for pelvic pathology (e.g.,
history of pelvic inflammatory disease, incomplete miscar-
riage, ectopic pregnancy, cervical dyskaryosis, and abdomi-
nal/pelvic/cervical surgery).Womenwith coexistingmorbid-
ity (e.g., autoimmune diseases, inflammatory conditions,
and diabetes mellitus) and those taking regular medications
were also excluded. The study protocol was approved by
National Research Ethics Service, Leeds (East) Research
Ethics Committee, and all participants provided written
informed consent.
All women underwent a baseline TVUSS (ALOKA SSSD
1700) in the early follicular phase. In the MNC cohort, a
TVUSS assessment was performed on alternate days from
day 8 of the cycle, until the mean maximal diameter (MMD)
measured in two planes (sagittal and transverse) of the
dominant follicle measured ≥14mm, after which they were
performed daily. Women were asked to use urinary LH kits
twice daily (06:00–08:00 and 18:00–20:00) in order to identify
the onset of LH surge prior to spontaneous ovulation. An
injection of 5,000 IU hCG (Pregnyl (Organon, Cambridge,
UK)) was given when the MMD of the lead follicle measured
≥17mm (17.0–18.1mm). If the urinary LH kit was positive,
ultrasound directed oocyte retrieval (UDOR) was performed
the day after the surge was detected; otherwise it was
planned for 36 h after hCG. For subsequent analysis, women
who had a spontaneous LH surge and women who were
administered exogenous hCG were grouped together as the
MNC cohort. All women in the COH arm underwent the
long protocol. Pituitary downregulation was attained using
leuprorelin acetate SR 3.75mg (Prostap (Wyeth, Maiden-
head, Berkshire, UK)) administered on the first day of the
menstrual cycle. COH was achieved with 225 IU human
menopausal gonadotropin (HMG) daily (Menopur, Ferring,
Slough, Berkshire, UK). As with the MNC-IVF/ICSI cycle,
when one ormore follicles had anMMDof ≥17mm, 5,000 IU
hCG (Pregnyl (Organon, Cambridge, UK)) was administered
36 h prior to UDOR.
All UDORs were performed between 09:00 and 11:00
to accommodate putative circadian variations in ovarian
physiology. Whole blood was collected immediately before
sedation in EDTAvacutainers. Dead space (containing 1.5mL
0.9% sodium chloride solution) within the oocyte harvesting
needle and tubing was constant/uniform throughout such
that the first 1.5mL aspirated was checked and discarded.
Subsequent aspirate was considered to contain FF and,
following oocyte assessment and retrieval, was subsequently
labelled to ensure longitudinal tracking of the corresponding
oocyte to its fate (for multifollicular cycles). Follicles were
flushed up to four times with culture medium (Enhance HTF
Culture Medium with HEPES; Conception Technologies,
San Diego, California, USA) if no oocyte was obtained in
the initial aspirate to minimise the risk of inadvertently
aspirating a second follicle and collecting the oocyte from the
previous one due to being contained within the dead space.
All ultrasonically visible follicles were individually aspirated
irrespective of their size. The aspiration pressure applied was
uniform on all follicles (183–185mm/Hg).
All samples were immediately stored on ice. Whole
blood and FF samples were centrifuged (2,000 rpm at 4∘C
for 10 minutes) to isolate plasma and remove cell debris,
respectively. All samples were frozen at −80∘C within one
hour of retrieval until required for analysis. In the MNC
cohort, only the FF from the single dominant follicle was
analysed. In the COH cohort, FF analysis was performed on
the follicles yielding the oocytes that generated transferred
embryos (since double ETs were performed in these cycles,
the follicle selected for analysis was the one yielding the
embryo with the highest morphological grading).
In both cycles, routine procedures for fertilization with
IVF/ICSI were performed as previously described [64].
Embryo transfer (ET) was performed 84–90 h after hCG
injection. A single ET was performed in the MNC cohort,
whilst a double ET was performed in the COH cohort (as per
ACU protocols at the time). All women in the MNC cohort
who underwent an ET received 2,500 IU hCG (Pregnyl)
on the day of ET and again 72 h later for luteal support.
Women in the COH cohort who developed <15 follicles had
an identical luteal support regimen, whereas those women
with ≥15 follicles following COH were given daily intra-
muscular injection of 100mg progesterone (Gestone, Nordic
Pharma, Reading, Berkshire, UK), which was continued
throughout the first trimester of pregnancy. Pregnancy tests
were performed on first void urine 14 days after ET with a
commercial urinary kit. A clinical pregnancy was defined as
one demonstrating a gestational sac with a fetal pole and a
fetal heart or an ectopic pregnancy by TVUSS at 6-7 weeks’
gestation.
2.2. Fluid-Phase Multiplex Immunoassay. Cytokine levels
in both FF and plasma were measured by fluid-phase
cytometric multiplex immunoassay (Bio-Rad Laboratories,
Hercules, CA, USA) (Bio-rad assays: Human Cytokine 27-
plex Assay M50-0KCAF0Y; Human Cytokine 21-plex Assay
MF0-005KMII) using a Luminex 100 cytometer (Luminex
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Corporation, Austin, Texas, USA) equipped with BioPlex 4.0
Manager software (Bio-Rad Laboratories, Ltd., Hertfordshire,
UK), as previously described [65]. Target cytokines included
interleukin- (IL-) 1 receptor antagonist (ra), IL-2ra, IL-3,
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13,
IL-15, IL-16, IL-18, leukaemia inhibitory factor (LIF), gran-
ulocyte macrophage-colony stimulating factor (GM-CSF),
macrophage- (M-) CSF, granulocyte- (G-) CSF, stem cell
factor (SCF), interferon- (IFN-) 𝛼, IFN-𝛾, IFN-𝛾 inducible
protein- (IP-10), TNF-𝛼, TNF-𝛽, TNF related apoptosis
inducing ligand (TRAIL), VEGF, platelet derived growth
factor (PDGF), basic fibroblast growth factor (b-FGF), nerve
growth factor- (NGF-) 𝛽, stem cell growth factor- (SCGF-
) 𝛽, growth regulated oncogene- (GRO-) 𝛼, macrophage
inflammatory protein- (MIP-) 1𝛽, monocyte chemoattractant
protein- (MCP-) 1,MCP-3, eotaxin, regulated upon activation
of normal T cell expressed and secreted (RANTES), stromal
cell-derived factor- (SDF-) 1𝛼, cutaneous T-cell attracting
chemokine (CTACK), monokine induced by IFN-𝛾 (MIG),
and macrophage migration inhibitory factor (MIF).
2.3. Contamination and Standardisation. Oocyte retrieval
frequently results in disruption of the intraovarian vascu-
lature such that blood (macroscopic or microscopic) con-
taminates the FF retrieved [66]. Furthermore, although the
needle and tubing were primed with normal saline at the
commencement of aspiration of each ovary, in between
subsequent follicular aspirations, protein-free flush medium
formulated with gentamicin (enhancedHTF culturemedium
with HEPES; Conception Technologies, San Diego, Califor-
nia, USA) was used, with potential dilution of the FF [67].
Such contamination/dilution was accounted for in the FF
cytokine analysis. This entailed cytokine, total protein (by
Lowry assay, Bio-Rad), and von Willebrand factor (vWF; by
enzyme-linked immunosorbent assay; R&D Systems, Abing-
don, UK) measurement in both plasma and FF. Since vWF
is a large plasma multimeric glycoprotein that does not pass
through the basement membrane and is not produced by
follicular cells, it enabled accurate quantification of FF blood
(and therefore circulatory cytokine) contamination (present
authors, manuscript under review). The dilutional effect of
the flushmediumwas instead accounted for by standardising
both FF and plasma (the latter to enable a valid comparison
with the former) cytokine concentrations to total protein (pg
cytokine/mg protein).
2.4. Statistical Analysis. Chi-squared, independent samples
𝑡-tests, or Mann-Whitney 𝑈 tests were used to compare
MNC and COH patient demographics, cycle details, FF, and
plasma cytokines following tests for normal distribution by
Shapiro-Wilk test (Stata/SE 11.1, Texas, USA). In order to
address the interrelationships between multiple cytokines
and the impact that COH has upon these, heat maps were
generated using R 2.7.0 software (R Foundation for Statistical
Computing, Vienna, Austria). Correlations between the dif-
ferent cytokines were determined for MNC and COH data
using Kendall’s tau as a measure of correlation (Stata/SE 11.1).
Resulting 𝑃 values were adjusted for multiple comparisons
withHolm’s correction (𝑃 < 0.05was considered significant).
3. Results and Discussion
3.1. Participant, MNC, and COH Cycle Demographics. In the
MNC cohort, one patient had a positive LH surge and there-
fore did not receive exogenous hCG. At the time of UDOR
12 hours after the positive surge, spontaneous ovulation had
occurred such that no FF was retrieved and an oocyte was
not obtained. This patient was therefore excluded from the
study. No statistically significant differences were noted in
patient demographics (age, BMI, baseline endocrine profile
(FSH, LH, and E
2
), and ethnicity), day of UDOR, follicular
aspirate volume, oocytematurity, and cycle outcome between
the two groups (Table 1).
3.2. Follicular Fluid and PlasmaCytokines. Most FF cytokines
(29 out of 40) were found to be at higher concentrations
in the MNC group compared to the COH group (binomial
test: 𝑃 < 0.001). This relationship was statistically significant
for LIF (𝑃 < 0.01) and SDF-1𝛼 (𝑃 < 0.05) (Figure 1). As
with FF, the majority of circulatory cytokines in the MNC
cohort were present at higher concentrations than in the
COH group (Figure 2), a relationship which was significant
for 12 of these: IL-2ra, IL-3, IL-12 (p40), LIF, M-CSF, IFN-
𝛼, TRAIL, NGF-𝛽, GRO-𝛼, MCP-3, RANTES, and SDF-1𝛼
(𝑃 < 0.05). Conversely, plasma IL-12 (p70) levels were present
at significantly higher levels following COH (𝑃 < 0.05)
(Figure 2).
Heat maps were generated following correlation analysis
using Kendall’s tau to demonstrate FF cytokine interrela-
tionships (Figure 3). Significantly more pairs of cytokines
exhibited strong correlations in the MNC data compared
to the COH data (binomial test) (𝑃 < 0.001). Various
relationship alterations were also noted; for example, LIF and
TNF-𝛼demonstrated aweak negative correlation in theMNC
group (Kendall’s tau: −0.08) compared with a strong posi-
tive correlation following COH (Kendall’s tau: 0.46). When
plasma:FF cytokine ratios were compared between the MNC
and COH cohorts, no statistically significant differences were
identified.
Gonadotropin use in COH has previously been recog-
nised to perturb the intrauterine cytokine milieu. Signifi-
cantly higher concentrations of various cytokines including
IL-1𝛽, IL-5, IL-10, IL-12, IL-17, TNF-𝛼, and eotaxin have been
recorded in endometrial secretions from stimulated cycles
compared to NCs [68]. Similarly, in the ovary, it has been
suggested that exogenous gonadotropins may influence the
levels of cytokines such as IL-1𝛽, IL-6, and TNF-𝛼 following
earlier studies on FF [69]. More recently, de Los Santos et al.
[70] demonstrated altered cumulus cell gene expression for
leukocyte differentiation and T-cell activation and regulation
following COH, which may in turn influence follicular
cytokine profiles as highlighted by the present findings.
To the best of our knowledge, FF has not previously
been analysed for such an extensive range of cytokines in
NC/MNC and COH cycles. In the present pilot study, FF
concentrations of 29 out of the 40 cytokines analysed were
found to be higher in the MNC cohort, significantly so for
LIF and SDF-1𝛼. LIF is an embryotrophic cytokine whose
secretion by GCs and stromal cells into FF has previously
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Figure 1: Mean (± SEM) FF cytokine concentrations in MNC (𝑛 = 9) and COH (𝑛 = 10) cycles (∗significant difference from COH cycle;
𝑃 < 0.05).
Table 1: Participant and cycle demographics in MNC and COH cycles.
NC Cycle COH Cycle 𝑃-value
Age (years) 30.8 ± 0.72 (27–34) 31.9 ± 1.20 (24–35) 0.21
BMI (kg/m2) 23.5 ± 0.86 (20.0–28.0) 24.0 ± 0.87 (20.0–30.0) 0.88
Baseline FSH (IU/L) 5.2 ± 0.40 (4.0–8.0) 6.0 ± 0.45 (3.9–7.9) 0.24
Baseline LH (IU/L) 5.2 ± 0.48 (2.6–7.1) 4.6 ± 0.55 (1.5–7.4) 0.44
Baseline E
2
(pmol/L) 115.2 ± 12.23 (73–162) 117.8 ± 18.14 (25–193) 0.92
Day of cycle for aspiration 14 ± 0.93 (10–20) 13.1 ± 0.34 (12–15) 0.35
Follicular volume (mL) 2.3 ± 0.40 (0.5–4.0) 3.0 ± 0.51 (1.0–6.5) 0.62
Mature oocyte (%) 70a 100b 0.06
Clinical pregnancy (%) 20c 30c 0.61
Mean ± SEM (range), unless otherwise specified. aOne patient spontaneously ovulated, therefore 9 oocytes were retrieved; bFollicles yielding a mature oocyte
which was subsequently transferred as an embryo were included in this cohort; cClinical pregnancy rate calculated per embryos transferred [MNC: 7 embryos
transferred; COH; 10 embryos transferred].
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Figure 2: Mean (± SEM) plasma cytokine concentrations inMNC (𝑛 = 9) and COH (𝑛 = 10) cycles (∗significant difference fromCOH cycle;
𝑃 < 0.05).
been shown to be stimulated by hCG [71–73]. Since both
the MNC and COH cohorts in this study received identical
doses of exogenous hCG, the elevated levels of LIF in MNC
FF may represent an enhanced response to hCG, whereas
the likely perturbed cytokine response allied to COH may
reflect a reduced sensitivity to hCG resulting in lower LIF
concentrations. COH also appeared to perturb relationships
between cytokines, highlighted by the relative changes in
intrafollicular LIF and TNF-𝛼 (where the latter modulates
ovarian stromal cell secretion of the former) [71]. The heat
map displays a strong positive correlation between LIF and
TNF-𝛼 in theMNC cohort whereas this relationship is weak-
ened following COH. Interestingly, FF LIF concentrations
have also been correlated with E
2
concentrations (possibly
through its role in enhancing aromatase expression) which,
in turn, relate to follicular maturity [74, 75]. Although a
comparable causal association has not been identified to
date in the ovary, 17-𝛽 oestradiol is known to induce LIF
synthesis in bovine oviduct epithelial cells [76]. It is tempting
to speculate that an analogous mechanism is at play in the
ovary, where the supraphysiological E
2
levels associated with
COH may impair the induction of follicular LIF synthesis,
with a consequent impact on the FFmilieu andoocyte quality.
SDF-1𝛼 is a chemokine secreted by oocytes, which acts in
a paracrine manner to prevent follicular activation, thereby
controlling the entry of primordial follicles into the growing
pool in NCs [77]. Furthermore, FF SDF-1𝛼 has previously
been positively correlated with FF VEGF levels in COH
cycles, where it is believed to play a proangiogenic role in
supporting follicular growth [78]. Our findings corroborate
this correlation in theCOHgroup (Figure 3). By contrast, this
relationshipwasmuchweaker in theMNCcohort, suggesting
that it may thus in part be gonadotropin dependent.
Akin to what was noted for FF, plasma cytokine levels
in the MNC group were higher than in COH cycles. The
exception was circulatory IL-12 (p70), which was measured
at significantly higher concentrations following COH. Fur-
thermore, correlations between FF IL-12 (p70) and other
cytokines weremarkedly altered following stimulation. In the
MNC cohort, most FF cytokines were positively correlated
with IL-12 (p70), whilst this relationship was reversed fol-
lowing COH. Conversely, IFN-𝛾 and TNF-𝛼 were negatively
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correlated with IL-12 (p70) in the MNC group and positively
in the COH cohort. Interestingly, an intricate triumvirate
relationship between these particular cytokines has been
identified in the regulation of inflammatory responses. IL-
12 (p70) induces IFN-𝛾 production [79] and, in turn, IFN-
𝛾 markedly augments IL-12 (p70) production, thereby pro-
viding a key inflammatory amplifying mechanism [80]. By
contrast, TNF-𝛼 is thought to inhibit IFN-𝛾-induced IL-12
(p70) production, as demonstrated by Hodge-Dufour et al.
[81], whose TNF+/+ mice exhibited a prompt inflammatory
response which resolved spontaneously compared with a
delayed, more vigorous, inflammatory response leading to
death associated with elevated IL-12 levels in TNF−/− mice
when injectedwithCorynebacterium parvum.Thus, TNF-𝛼 is
thought to contribute to the resolution of IL-12- (p70-) driven
inflammatory processes. In the MNC cohort, TNF-𝛼 was
negatively correlated with both IL-12 (p70) and IFN-𝛾, thus
suggesting that, in the absence of stimulatory gonadotropins,
TNF-𝛼 of follicular cell origin may play an analogous role
via its capacity to regulate IL-12 (p70) production. A positive
correlation between these FF cytokines in combination with
significantly elevated systemic IL-12 (p70) levels suggests a
disruption of this mechanism following COH. An analogous
disruption in the ovary following COH could thus contribute
to the detrimental sequelae of increased IL-12 (p70) and
IFN-𝛾 levels despite the observed compensatory rise in
modulatory TNF-𝛼 levels.
Fluctuations in systemic white cell populations have
been attributed to stimulationwith exogenous gonadotropins
such that the total number of circulatory leukocytes and
neutrophils was increased on the day of hCG administration
in COH compared to NCs [82]. Other studies have reported
an increase in plasma white cell count and G-CSF, but not
in M-CSF or IL-6, during COH [83]. Furthermore, various
8 International Journal of Reproductive Medicine
cytokines have been found to be elevated in FF following
COH, including IL-1𝛽, IL-6, and TNF-𝛼 [69]. The main
difference between the present study and those cited is
our administration of exogenous hCG in the MNC cohort.
Both LH and hCG induce IL-1𝛽 and TNF-𝛼, both of which
subsequently upregulate GM-CSF expression [38]. Despite
identical doses of hCG being used to trigger ovulation in
both groups in the current study, GM-CSF in particular was
measured at higher (although not statistically significant)
levels following COH in both FF and plasma. Furthermore,
following COH, there was a trend towards several other
proinflammatory cytokines in both FF and plasma to be
found at higher concentration, with IL-12 (p70) levels in
particular being significantly higher in COH plasma sam-
ples. This provides further evidence that COH can induce
both local and systemic inflammatory network deregulations
featuring perturbations in cytokine interrelationships which,
speculatively,may potentially also impact oocyte viability and
treatment outcome. Unfortunately, the present pilot study
was not powered to answer this particular question.
4. Conclusions
In conclusion, this investigation demonstrated that COH
not only alters FF cytokine profiles compared to MNCs
but also perturbs their circulatory levels and disrupts their
interrelationships. Given their central role in orchestrating
normal follicular physiology, these changes have the potential
to adversely affect follicular function and compromise oocyte
viability.
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